Minimal-Change Disease

Updated: Feb 08, 2023
Author: Abeera Mansur, MD; Chief Editor: Vecihi Batuman, MD, FASN 


Practice Essentials

Minimal-change disease (MCD), also known as lipoid nephrosis or nil disease, arises from a histopathologic lesion in the glomerulus and is characterized by intense proteinuria leading to edema and intravascular volume depletion.[1] It is the most common single form of nephrotic syndrome in children, but it can also occur in adults.[2]

On laboratory testing, profound proteinuria and oval fat bodies may be observed. In children, the critical level for diagnosis is proteinuria of more than 40 mg/h/m2. In adults, the threshold is more than 3.5 g/d/1.73 m2. (See Workup.)

Treatment includes measures to clear proteinuria, reverse hypovolemia, and reduce edema. Corticosteroids are the treatment of choice, leading to complete remission of proteinuria in most cases. Recurrence is common, however. Options for steroid-sparing therapy and steroid-resistant cases include cyclophosphamide, chlorambucil, mycophenolate, rituximab, and tacrolimus. See Treatment and Medication.

For patient education information, see the Nephrotic Syndrome Overview.


It is postulated that MCD is a disorder of T cells, which release a cytokine that injures the glomerular epithelial foot processes. This, in turn, leads to a decreased synthesis of polyanions. The polyanions constitute the normal charge barrier to the filtration of macromolecules, such as albumin. When the polyanions are damaged, leakage of albumin follows. The identity of this circulating permeability factor is uncertain, although it is postulated that it may be hemopexin.

Some of the cytokines that have been studied in MCD are interleukin-12 (IL-12) and interleukin-4 (IL-4). IL-12 levels have been found to be elevated in peripheral blood monocytes during the active phase and normalized during remission. Interleukin-18 (IL-18) can synergize with IL-12 to selectively increase the production of vascular permeability factor from T cells. In addition, levels of IL-4 and CD23 (a receptor for immunoglobulin E [IgE][3] ) have been found to be elevated in peripheral blood lymphocytes.

Synaptopodin is a proline-rich protein intimately associated with actin microfilaments present in the foot processes of podocytes. Greater synaptopodin expression in podocytes is associated with a significantly better response to steroid therapy. On the other hand, the expression of synaptopodin does not predict progression of MCD or diffuse mesangial hypercellularity to focal segmental glomerulosclerosis (FSGS). Thus, this marker could be used in the future to help determine appropriate therapy.

Interleukin-13 (IL-13) has been implicated in the pathogenesis of MCD. In a study on Chinese children in Singapore, it was shown that IL-13 genetic polymorphisms correlate with the long-term outcome of MCD.[4] An animal study by Lai et al suggested that IL-13 overexpression can cause podocyte foot process fusion and proteinuria.[5]

In patients who develop acute kidney injury (AKI), endothelin 1 expression is greater in the glomeruli, vessels, and tubules than in the non-AKI group. The glomerular epithelial cells (podocytes) and the slit diaphragm connecting the podocyte foot processes play a primary role in the development of proteinuria.

Nephrin is a major component of the slit diaphragm and is critical for preserving the glomerular capillary barrier to protein.[6] The slit diaphragm is often missing in MC nephrotic syndrome (MCD) kidneys. 

CD80 is a protein expressed on the surface of several antigen-presenting cells. It is also expressed on podocytes, and increased expression of CD80 has resulted in a reduced expression of nephrin. Urinary levels of CD80 are increased in patients with MCD but not in patients with FSGS. Thus, this may have clinical applicability in distinguishing these two entities.[7]

In a study of 37 patients with MCD, 27 patients with FSGS, 30 patients with other glomerulopathies, and 71 healthy controls, Ling and colleagues found that urinary CD80 concentrations were significantly higher in patients with active MCD compared with patients with FSGS or other glomerulopathies and controls. At a cutoff value of 328.98 ng/g creatinine, urinary CD80 had a sensitivity of 81.1% and a specificity of 94.4% for diagnosing MCD.[8]  

A study by Ahmed et al in 36 children with nephrotic syndrome and normal glomerular filtration rate, which included 21 chlidren with MCD, found that urinary CD80 levels were significantly higher in patients with MCD than in those with FSGS (3.5 ± 2.1 versus 1.2 ± 0.5 ng/mg creatinine; P < 0.001). CD80 levels were also higher in patients with MCD than in those with other glomerulopathies or normal controls (n=40).  A urinary CD80 cutoff value of 1.5 ng/gm creatinine showed a sensitivity of 100% and a specificity of 86% for diagnosis of MCD.[9]

Izzedine et al found a lack of glomerular dysferlin expression associated with minimal-change nephropathy in a patient with limb-girdle muscular dystrophy type 2B.[10]  In the same study, 2 of 3 other patients with dysferlinopathy had microalbuminuria.

B-cell–depleting agents have shown efficacy in the treatment of MCD, which suggests that B-cells may have a role in the pathogenesis of MCD.[11] Additionally, anti-nephrin antibodies may also play a role in the pathogenesis of MCD.[12]


Almost all cases of MCD are idiopathic, but a small percentage of cases (approximately 10-20%) may have an identifiable cause. Secondary cases may be due to any of the following:

  • Drugs - Nonsteroidal anti-inflammatory drugs (NSAIDs), rifampin, interferon, ampicillin/penicillin, trimethadione, mercury-containing cosmetic skin cream, immune checkpoint inhibitors [13]
  • Toxins - Mercury, [14]  lithium, bee stings, fire coral exposure [15]
  • Infection - Infectious mononucleosis, HIV, immunization
  • Tumor - Hodgkin lymphoma [16]  (most commonly), carcinoma, other lymphoproliferative diseases
  • Hematopoietic stem cell transplantation [17]

Cases of both new-onset and relapsing MCD have been reported following COVID-19 immunization with the Pfizer-BioNTech COVID-19 vaccine.[18, 19, 20]



United States

In preadolescents, minimal-change nephrotic syndrome (MCNS) makes up 85-95% of all cases of nephrotic syndrome. In adolescents and young adults, the prevalence is 50%, while in adults, MCNS accounts for 10-15% of primary nephrotic syndrome cases. The incidence of nephrotic syndrome is 2-7 new cases annually per 100,000 children, and the prevalence is 15 cases per 100,000 children.

Race-, sex-, and age-related demographics

Rates of MCD vary as follows:

  • Asians may be at increased risk for MCD
  • In children, MCD is found twice as frequently in boys than in girls; in adults, however, the frequency is the same between the sexes
  • The incidence of MCD peaks in children aged 2 years, with approximately 80% being younger than 6 years at the time of diagnosis
  • In adults, the mean age of onset is 40 years


Very few patients progress to end-stage renal disease. These are patients who have FSGS that has been misdiagnosed as MCD.

Hypovolemic shock is perhaps the most serious complication of MCD. Hypovolemic shock typically occurs during the edema-forming phase of relapse and may be precipitated by diarrhea, sepsis, drainage of ascitic fluid, or the use of diuretics.

Hypertension, somewhat paradoxically, also may occur in approximately 9-14% of children. Hypertension occurs in approximately 30% of adults, with a greater incidence in older patients (>60 y).

Thromboembolic events are serious complications of nephrotic syndrome. Peripheral thrombosis may result in gangrene, and deep venous thrombosis in the legs or pelvic veins may be a source of pulmonary emboli. Bacterial infections, especially peritonitis, occur with greater frequency, partly because of the loss of immunoglobulin G (IgG) and complement factors B and D in the urine. In fact, the largest reduction in mortality in these patients follows the introduction of antibiotics rather than any specific therapy.


Use of antibiotics and glucocorticoids and better-organized schedules of management have substantially reduced the mortality rates associated with MCD. Deaths still occur from disease complications.

The most common complications of MCD are the adverse effects of medications. Additional complications may include peritonitis, infections, and acute kidney injury (AKI). AKI occurs because of either acute tubular necrosis or acute tubulointerstitial nephritis. In a retrospective review of 95 adult patients with MCD, Waldman et al reported that 24 patients had AKI, with these individuals tending to be older and hypertensive, and to have lower serum albumin and more proteinuria than did patients who did not suffer AKI.[21]

Patients with nephrotic syndrome have an increased incidence of arterial and venous thromboemboli, particularly deep vein and renal vein thrombosis. Renal vein thrombosis is known to occur in patients with MCD, although the incidence is lower than in patients with membranous nephropathy.

Hypercholesterolemia and hypertriglyceridemia can lead to accelerated atherosclerosis and perhaps cause progressive glomerular injury.

Relapses eventually cease. Only approximately 5% of children continue to have steroid-responsive relapses when older than 18 years.

Ling et al reported that urinary levels of CD80 have prognostic value in chlidren with MCD. In their study of 64 children with nephrotic syndrome, progression to chronic kidney disease occurred in 2.9% of those with CD80 levels above 328.98 ng/g creatinine, compared with 41.4% of those with levels below that threshold (P < 0.001). The predicted response to immunosuppressive therapy was 100% in patients with high urinary CD80 levels, versus 34.5% in those with low levels (P < 0.001).[22]

Adults have a similarly good prognosis. Survival rates of 85-90% are observed 10 years or more after disease onset. An observational study of 78 adult patients found that although 10% were steroid-resistant, 98% achieved remission by a median of 5 weeks; 61% relapsed, at a median of 11 months, and patients had a median of 2 relapses during follow-up. Risk of relapse was increased in patients with a higher estimated glomerular filtration rate, and early relapse occurred significantly more often in women. Five patients subsequently developed focal segmental glomerulosclerosis; those patients had a lower baseline creatinine, a higher serum albumin, and a longer time to remission and were more likely to have steroid-resistant disease.[23]

Chronic kidney disease is extremely rare in patients whose MCD is steroid responsive. If chronic kidney disease occurs, the possibility that the pathologic lesion is different or has evolved must be considered.

Patient Education

Patient education in MCD includes the following:

  • Explain the consequences of not receiving treatment for MCD
  • Explain to the family that children with MCD initially are treated without a tissue diagnosis
  • Explain the possible adverse effects of therapy, including growth retardation in children receiving long-term corticosteroids
  • Explain that not all patients receiving treatment respond to conventional therapies
  • Advise family members to be observant for edematous changes in the patient
  • Refer the patient and family for psychosocial counseling
  • Impose moderate sodium restrictions and ensure adequate protein intake

For patient education information, see the Nephrotic Syndrome Overview.




Facial edema is noted first. Edema may be preceded by an upper respiratory tract infection, an allergic reaction to a bee sting, the use of certain drugs, or malignancies.

Malaise and easy fatigability can occur. Weight gain often is an additional feature.

The patient also may present with one or more of the following:

  • Hypovolemia
  • Hypertension
  • Thromboembolism
  • Infection

Physical Examination

The blood pressure usually is normal in children[24] but may be elevated in adults. (In addition, the plasma creatinine in adults is often slightly elevated at presentation.)

Dependent edema is the most prominent sign. The retina has a wet appearance. Subungual edema with horizontal lines (called Muehrcke lines) also may occur.

Hernias may be found, and the elasticity of the ears may be decreased.

Heavy proteinuria over an extended period of time leads to a state of protein depletion with muscle wasting, thinning of the skin, and growth failure.

Pleural and ascitic fluid can accumulate. Rarely, cellulitis, peritonitis, or pneumonia may be the first indication of an underlying nephrotic syndrome.

Children may have growth failure.



Diagnostic Considerations

Other problems to be considered include the following:

  • C1q nephropathy
  • Focal segmental glomerulosclerosis
  • Immunoglobulin M (IgM) nephropathy
  • Membranous nephropathy


Approach Considerations

Urinalysis findings are benign in minimal-change disease (MCD), but profound proteinuria and oval fat bodies may be observed. In children, the critical level for diagnosis is proteinuria of more than 40 mg/h/m2. In adults, the threshold is more than 3.5 g/d/1.73 m2.

A random albumin-to-creatinine concentration ratio is in excess of 5. Urine specific gravity is high because of proteinuria. A 24-hour urine measurement should be obtained for protein and creatinine clearance.

Hypoalbuminemia is an important marker of nephrotic syndrome. The level at which edema occurs varies, but it tends to be lower in children than in adults. Nephrotic syndrome in children is defined by a serum albumin of less than 2.5 g/dL. Hyperlipidemia also is a feature of a nephrotic state.

Other laboratory findings are as follows:

  • Kidney function usually is normal except in cases of undiagnosed focal segmental glomerulosclerosis (FSGS) or in those cases that progress to acute kidney injury

  • Serologic workup (including antinuclear antibodies, complements, and cryoglobulins) is normal

  • Hyponatremia is often observed and is in part a spurious finding secondary to the hyperlipidemic state; it also occurs from water retention caused by hypovolemia and antidiuretic hormone release

  • Elevated hemoglobin and hematocrit are consequences of plasma volume contraction

Renal sonogram results are normal in patients with MCD.

Because MCD accounts for 90% of all cases of idiopathic nephrotic syndrome in children, kidney biopsy is not part of the initial workup for MCD in that age group. Instead, biopsy is performed only in those children who fail to achieve remission with an empiric course of corticosteroids. In contrast, a kidney biopsy is performed in all adult patients with nephrotic syndrome, before the initiation of treatment for MCD.

Increasing interest centers on the possibility of using urinary levels of CD80 as a biomarker in MCD (see Pathophysiology and Prognosis). Elevated levels may help differentiate MCD from FSGS[7] and predict responsiveness to corticosteroids.[22, 25]

Histologic Findings

Light microscopy

In patients with MCD, the glomerulus is, by definition, normal or nearly so when examined with the light microscope; however, the precise limits of normal are not clearly defined. This creates difficulty in differentiating the appearance of minimal change with mild mesangial proliferation from a mesangial proliferative glomerulonephritis. Diagnosis can be even more difficult because, at the peak age of onset (approximately 3 y), the mesangial and epithelial cells are more prominent. In adult patients, diagnosis is made more challenging by superimposed arterionephrosclerosis secondary to hypertension.

In children with frequently relapsing MCD, some involuted glomeruli may be present. These lesions are small and sclerotic but retain their podocyte and parietal epithelial cell constituents. The presence of these glomeruli is related to the duration of the disease.

The most common tubular lesion is protein and lipid droplets in epithelial cells due to increased reabsorption. The presence of areas of tubular atrophy and interstitial fibrosis should raise the suspicion of FSGS.


These studies usually do not demonstrate significant glomerular deposition of immunoglobulins or complement components in patients with MCD. Some biopsy specimens may be positive for low-level IgM deposits not accompanied by mesangial dense deposits.

Electron microscopy

Retraction of the epithelial foot processes is observed consistently in patients with MCD. This is, at times, erroneously described as foot-process fusion and results from disordered epithelial cell structure with withdrawal of the dendritic process. This finding is not unique to MCD, and the diagnosis is one of exclusion of other diseases based on lack of other processes on light microscopy, immunohistology, or electron microscopy.



Approach Considerations

Because of the high prevalence of minimal-change disease (MCD) in children with nephrotic syndrome, an empiric trial of corticosteroids commonly is the first step in therapy. Corticosteroids are the treatment of choice, leading to complete remission of proteinuria in most cases. Approximately 90% of children respond within 2 weeks to prednisone at a dose of 2 mg/kg/day (not to exceed 80 mg/day). After the remission of proteinuria, prednisone is continued for another 6 weeks, at lower doses.

In some children, proteinuria fails to clear by 6-8 weeks, and performing a kidney biopsy may be useful to determine if another process may be present. For example, MCD secondary to Hodgkin lymphoma is frequently resistant to steroids and will remit with cure of the primary disease. Generally, if proteinuria persists after two relapses or courses of steroids, a tissue diagnosis should be made before starting cytotoxic or immunosuppressive therapy.

Adults respond more slowly than children. A response in up to 80%-90% of cases has been recorded in adolescents and adults, but the time to remission is up to 16 weeks. In patients with steroid-resistant MCD or frequent relapses, a trial of immunosuppressants is given.

A Cochrane review of treatments of nephrotic syndrome in adults with MCD reported that calcineurin inhibitors (eg, tacrolimus, cyclosporine) with or without low-dose prednisolone were as effective as prednisolone alone in achieving remission, with lower rates of adverse effects.[26]

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), alone or in combination, should be used with a goal of reducing the proteinuria. Blood pressure and kidney function should be monitored closely in patients on ACE inhibitors and ARBs.

The presence of hypovolemia necessitates immediate volume expansion with purified plasma protein fraction and isotonic saline. Parenteral albumin infusions are not appropriate for long-term management of hypoalbuminemia because they have only a transient effect. Such crises should be avoided with recognition of the earlier signs of hypovolemia, including abdominal pain and increase in hematocrit, and correction of contributing factors (eg, diarrhea, septicemia, diuretic therapy).

Edema should be controlled by dietary sodium restriction. Small amounts of edema have little clinical significance. The use of diuretics should be reserved for patients with severe edema, particularly in the presence of respiratory or gastrointestinal symptoms, and when the condition restricts activity.

Thrombotic episodes should be prevented by mobilization and meticulous attention to venipuncture and intravenous infusion sites. Established episodes should be managed with heparinization.

Infections must be treated aggressively. Cellulitis, peritonitis, otitis, and pneumonia are common infections. Susceptibility to pneumococcal infections warrants the administration of penicillin prophylaxis to patients in relapse. Corticosteroids increase susceptibility to infection.


Consultation with a nephrologist generally is needed. The nephrologist has the expertise to perform and interpret the kidney biopsy. A renal pathologist has the expertise to interpret biopsy findings under light microscopy, immunofluorescence, and electron microscopy.

Diet and Activity

An adequate dietary protein intake, in accordance with the recommended daily allowance (RDA) is necessary. No evidence suggests that protein intake that is higher than the RDA will elevate hepatic albumin synthesis.

Dietary sodium restriction helps forestall the progression of edema and also is prudent in the management of hypertension.

Mobilization, rather than bed rest, is indicated to avoid thromboembolic complications.

Long-Term Monitoring

Followup care includes the following:

  • Carefully monitor medication doses and adverse effects
  • Monitor vital signs for possible onset of hypertension
  • Monitor volume status
  • Monitor for signs of infection


Medication Summary

Pharmacologic treatment in patients with minimal-change disease (MCD) includes the use of diuretics to decrease severe edema. Nonsteroidal anti-inflammatory drugs (NSAIDs) also can be used to decrease proteinuria.

MCD usually responds to corticosteroids. The response is defined in terms of proteinuria, as follows:

  • Complete remission - Complete resolution of proteinuria for at least 3-5 consecutive days
  • Partial remission - Reduction in the degree of proteinuria without complete clearing
  • Relapse - Reoccurrence of proteinuria for at least 3-5 consecutive days

A typical initial regimen in adults consists of oral prednisone in a daily dosage of 1 mg/kg of body weight for 8-16 weeks (or for 1 wk after remission has been induced). The patient is then placed on an alternate-day single-dose (1 mg/kg) regimen to minimize the incidence of adverse effects. If proteinuria disappears or falls to a very low level, high-dose alternate-day therapy is continued for several weeks to 1 month and prednisone is then slowly tapered over several months in an attempt to reduce the likelihood of relapse.

Patients with steroid-sensitive MCD have complete remission within 8-12 weeks with infrequent relapses. Children usually respond within 4-6 weeks. Adults tend to respond slowly, with more than 25% taking as long as 12-16 weeks to attain complete remission. Treatment usually is continued for another 6 weeks after complete remission of proteinuria occurs.

First-line treatment with tacrolimus proved an effective alternative to steroid therapy in a multicenter, prospective, open-label, randomized, controlled trial in 50 adult patients with MCD. Rates of complete remission at 8 weeks were 68% (17 of 25 patients) with tacrolimus versus 84% (21 of 25 patients) with prednisolone (P=0.32). In patiens who achieved complete remission, there was no significant difference between the two cohorts in relapse rates or in the time from complete remission to relapse. The authors conclude that tacrolimus is an effective alternative for patients with MCD who wish to avoid steroid therapy.[27]

If remission of MCD is followed by recurrence, a second course of steroids is given. Those patients who need steroids repeatedly are categorized as frequent relapsers or steroid dependent. Relapse in these patients can occur either during tapering of steroids or after cessation of therapy. In these patients, cytotoxic drugs (eg, cyclophosphamide, chlorambucil, or cyclosporine) can be considered to either induce a remission or decrease the adverse effects of continuous steroid use. Adults are particularly prone to the adverse effects of corticosteroids, but they do well on cyclophosphamide.

Studies in adults and children have shown that both cyclophosphamide and cyclosporine added to steroid treatment may induce remission.[28] Moreover, if these patients relapse at a later time, they tend to become steroid-sensitive.

Cyclophosphamide may be given in a dosage of 2 mg/kg/d for 8-12 weeks. Cyclosporine is given in a dosage of 4-6 mg/kg/d and also can be used in patients who continue to relapse or who are steroid-dependent.

Because cyclophosphamide is less expensive than cyclosporine and has a better response rate, it is preferable to cyclosporine in most patients with steroid-dependent or frequently relapsing MCD. However, cyclosporine may be used as an alternative to cyclophosphamide in order to avoid toxicities associated with the latter.[29] Keeping the dosage of cyclosporine at a minimum and carefully monitoring the drug’s levels have been shown to be helpful in avoiding cyclosporine-associated nephrotoxicity.

In children, repeat kidney biopsy can alter the treatment plan in a significant number of patients. Long-term follow-up of patients with MCD persisting after puberty shows that they are at increased risk of osteoporosis, myopia, and hypertension.

In patients who do not respond to treatment, follow-up biopsies have been found to show either IgM nephropathy or focal segmental glomerulosclerosis (FSGS). A study by Swartz et al of 55 children with steroid-resistant or steroid-dependent MCD determined that 23 of these patients also had mesangial IgM that was visible with immunofluorescence (one of the characteristics of IgM nephropathy).[30] The investigators also found that the children with MCD and immunofluorescently-visible IgM responded better to treatment with cyclosporine than to therapy with cyclophosphamide.

In cases where conventional immunosuppressive therapy has failed, the anti-CD20 antibody rituximab has demonstrated reasonable efficacy and an acceptable adverse effect profile.[31, 32, 33, 34]  Fenoglio et al reported successful use of rituximab as first-line therapy in six adult patients with MCD, and suggest that rituximab may be preferentially used in patients at high risk for adverse effects from corticosteroids.[35]  

Rituximab may be effective in relapsed MCD because relapse has been linked to the reappearance of B19 cells, which rituximab depletes. However, randomized controlled trials need to be conducted before guidelines can be issued.[32, 36, 37]  

In 20% of steroid-resistant patients, a genetic mutation may be responsible. One of these is the NPHS2 mutation; however, heterozygotes respond well to steroids.[38]

In children with steroid-resistant nephrotic syndrome, Gulati et al reported that those who received the calcineurin inhibitor tacrolimus and steroids had a higher complete/partial remission rate and increased chances of sustained remission with fewer adverse effects compared with those who received cyclophosphamide.[39] A Chinese study in patients with adult-onset minimal change nephrotic syndrome found that tacrolimus monotherapy after short-term intravenous methylprednisolone was noninferior to conventional glucocorticoid treatment.[40]

Mycophenolate mofetil (MMF) has been shown in limited studies to be beneficial in patients with steroid-dependent or frequently relapsing MCD.[41, 42, 43] Similarly, the immune modulator levamisole has shown benefit in small trials.[44]

For the treatment of frequently relapsing or steroid-dependent MCD, the Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group recommends cyclophosphamide in patients with no previous cyclophosphamide exposure and no treatment preference. For patients who received cyclophosphamide previously or who wish to avoid cyclophosphamide, treatment options are rituximab, calcineurin inhibitors, and MMF/sodium mycophenolate.[45]


Class Summary

These agents control volume overload.

Furosemide (Lasix)

Has potent diuretic effects by blocking the sodium reabsorption in the thick ascending limb of the loop of Henle.


Class Summary

For remission of proteinuria.

Prednisone (Sterapred)

Exerts anti-inflammatory effect via the inhibition of inflammatory mediator gene transcription.

Antineoplastic agents

Class Summary

For remission of nephrotic syndrome.

Cyclophosphamide (Cytoxan, Neosar)

Interferes with normal function of DNA by alkylation and cross-linking strands of DNA and by possible protein modification.

Immunosuppressant agents

Class Summary

For remission of nephrotic syndrome.

Cyclosporine A (Sandimmune, Neoral)

Inhibits production and release of IL-2, leading to inhibition of IL-2–mediated activation of T lymphocytes.

Chlorambucil (Leukeran)

To induce remission of proteinuria. Interferes with DNA replication and RNA transcription.

Tacrolimus (Astagraf XL, Envarsus XR, Hecoria)

Calcineurin inhibitor; inhibits T-cell activation and proliferation, humoral immunity.


Class Summary

To induce remission of nephrotic syndrome.

Levamisole (Ergamisol)

Stimulates formation of antibodies and enhances T-cell responses. Acts as a biochemical modulator of fluorouracil.

Mycophenolate mofetil (CellCept)

Inhibitor of de novo purine pathway with preferential inhibitory effects on T and B lymphocyte proliferation, has been used to treat steroid-dependent nephrotic syndrome.


Questions & Answers


What is minimal-change disease (MCD)?

What is the pathophysiology of minimal-change disease (MCD)?

What is the prevalence of minimal-change disease (MCD) in the US?

Which patient groups have the highest prevalence of minimal-change disease (MCD)?

What is the mortality and morbidity associated with minimal-change disease (MCD)?


Which clinical history findings are characteristic of minimal-change disease (MCD)?

What are the signs and symptoms of minimal-change disease (MCD)?

Which physical findings are characteristic of minimal-change disease (MCD)?

What causes minimal-change disease (MCD)?


Which conditions are included in the differential diagnoses of minimal-change disease (MCD)?


How is minimal-change disease (MCD) diagnosed?

What is the role of biomarkers in the diagnosis of minimal-change disease (MCD)?

Which light microscopy findings are characteristic of minimal-change disease (MCD)?

Which immunohistologic findings are characteristic of minimal-change disease (MCD)?

Which electron microscopy findings are characteristic of minimal-change disease (MCD)?


How is minimal-change disease (MCD) treated?

Which specialist consultations are beneficial to patients with minimal-change disease (MCD)?

Which dietary and activity modifications are used in the treatment of minimal-change disease (MCD)?


What is the role of medications in the treatment of minimal-change disease (MCD)?

How is the response to steroids determined in the treatment of minimal-change disease (MCD)?

Which medications are used in the treatment of minimal-change disease (MCD)?

Which medications in the drug class Immunomodulators are used in the treatment of Minimal-Change Disease?

Which medications in the drug class Immunosuppressant agents are used in the treatment of Minimal-Change Disease?

Which medications in the drug class Antineoplastic agents are used in the treatment of Minimal-Change Disease?

Which medications in the drug class Corticosteroids are used in the treatment of Minimal-Change Disease?

Which medications in the drug class Diuretics are used in the treatment of Minimal-Change Disease?